Navigation Links
VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
Date:5/13/2009

Enrollment in First Pivotal Phase 3 Avanafil Study REVIVE (TA-301) is Complete

MOUNTAIN VIEW, Calif., May 13 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today announced that it has initiated an open label safety study (TA-314) with its investigational drug, avanafil, in males with erectile dysfunction (ED).

VIVUS also announced today that it has completed enrollment in REVIVE (TA-301), a randomized, double-blind, placebo-controlled phase 3 study of avanafil in men with a history of generalized ED and the first of several planned phase 3 studies of avanafil. Approximately 650 patients have been enrolled in the study. Top-line results of REVIVE are expected in the fourth quarter of 2009.

Avanafil, a next-generation, fast-acting, selective, oral, phosphodiesterase type 5 (PDE5) inhibitor, is VIVUS' investigational product for the treatment of ED. The phase 3 program for avanafil is funded through a $30 million collaboration with Deerfield Management.

"We continue to make excellent progress on the avanafil phase 3 program, and are pleased with the rapid rate at which we accrued patients in our first pivotal study, REVIVE," commented Charles Bowden, MD, senior director of clinical development at VIVUS. "Initiation of the TA-314 safety study is a critical step in advancing avanafil toward an NDA filing. We are confident that avanafil will provide a much needed new option for the millions of men living with ED, and we look forward to announcing data from both of these studies later this year and next."

The open-label study is being conducted in approximately 600 patients across 40 U.S. centers. Patients completing either the 12-week REVIVE or R
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
6. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
7. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
10. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
11. Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014 /CNW/ - Atlantic Canadians will ... reached between Canada,s provinces and ... , President of the Canadian Generic Pharmaceutical Association (CGPA), ... comments while speaking at the Atlantic Summit on Healthcare ... , which is being hosted by the Public Policy ...
(Date:10/30/2014)... -- Zimmer Holdings, Inc. (NYSE: ZMH and ... and organizational structure of the combined company following the ... the combined organization will leverage the strength of both ... the new brand to be rolled out across the ... future leadership team is committed to establishing Zimmer Biomet ...
(Date:10/30/2014)... -- CVS Health (NYSE: CVS ) announced today ... regional health systems to enhance access to high-quality, affordable health ... Health System in Alabama ; Community Health ... Pennsylvania , Northwest Medical Center, including Oro Valley ... in Tennessee ; and Premier Health in ...
Breaking Medicine Technology:Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4
... NEW YORK, March 24, 2011 Reportlinker.com announces ... in its catalogue: Assistive Devices ... http://www.reportlinker.com/p0461658/Assistive-Devices-for-Special-Needs-Technologies-and-Global-Markets.html ... of devices and accommodation products for several categories ...
... NEW YORK, March 24, 2011 Reportlinker.com announces that ... catalogue: Therapeutics for Immune System ... In 2010, the global market for drugs for ... approximately $72.2 billion.  The market size is forecast to ...
Cached Medicine Technology:Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 2Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 3Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 4Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 5Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 6Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 7Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 8Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 9Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 10Reportlinker Adds Assistive Devices for Special Needs: Technologies and Global Markets 11Reportlinker Adds Therapeutics for Immune System Disorders 2Reportlinker Adds Therapeutics for Immune System Disorders 3Reportlinker Adds Therapeutics for Immune System Disorders 4Reportlinker Adds Therapeutics for Immune System Disorders 5Reportlinker Adds Therapeutics for Immune System Disorders 6Reportlinker Adds Therapeutics for Immune System Disorders 7Reportlinker Adds Therapeutics for Immune System Disorders 8Reportlinker Adds Therapeutics for Immune System Disorders 9Reportlinker Adds Therapeutics for Immune System Disorders 10Reportlinker Adds Therapeutics for Immune System Disorders 11Reportlinker Adds Therapeutics for Immune System Disorders 12Reportlinker Adds Therapeutics for Immune System Disorders 13
(Date:10/31/2014)... October 31, 2014 Springboard Biodiesel, ... its small scale BioPro™ biodiesel processors, announced on ... further improve the performance and efficiency of small-scale ... GL95/MC12/BD380 trio will recover more than 99% ... with the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... Missouri (PRWEB) October 31, 2014 At ... country about families narrowly escaping carbon monoxide poisoning in ... looms just weeks away, one family-owned, Missouri-based heating and ... approach to making sure families start the home heating ... safe and secure. , Beginning Nov. 1, 2014, ...
(Date:10/31/2014)... -- Surgery for low back pain caused by spinal ... you live, a new report says. "Nearly 80 ... some point in their lives, and about 30 million ... spine problem," co-author Brook Martin, of the Dartmouth Institute ... college news release. In spinal stenosis, thickening of ...
(Date:10/31/2014)... DARIEN, IL – New research suggests that insomnia is ... crashes and other unintentional fatal injuries. The results underscore ... of the National Healthy Sleep Awareness Project. , Results ... in a dose-dependent manner with the number of insomnia ... were 2.8 times more likely to die from a ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... ANN ARBOR, Mich. The use of a pedometer and ... be powerful motivators for people with diabetes who participated in ... of Michigan Health System and VA Ann Arbor Healthcare System. ... be more effective than others. , All participants in the ...
... November 19, 2007Health care providers, insurance companies and drug ... public, according to a new survey of leaders in ... Healthcare Health Care Opinion Leaders Survey finds widespread support ... provider quality and prices, 86 percent of respondents support ...
... most harmful strains of human papillomavirus is under study ... called nine-valent, is being compared with Gardasil, a quadrivalent ... two most deadly HPV types. , Were testing Gardasil ... Dr. Daron Ferris, family medicine physician and director of ...
... Eating disorders in the U.S. among ethnic groups were ... that many cultures are now exposed to the thin ... an increase in eating disorder symptoms among ethnic groups. ... control behaviors may be increasing among adolescent boys. ...
... that in cell cultures, the stress hormone norepinephrine appears ... cells to grow and spread. , The finding, ... progression and spread of some cancers enough so that ... work. , The study also showed that stress ...
... Nov. 19 ARJO, Inc. USA announces the,opening ... Coast showroom in Costa Mesa,(Orange County) California. The ... evaluate ARJO Extended Care Products,GETINGE Infection Control and ... (CS) settings. MAQUET Surgical Workplace products, for ...
Cached Medicine News:Health News:Pedometers motivate people with diabetes to walk more 2Health News:Pedometers motivate people with diabetes to walk more 3Health News:Health care opinion leaders support public reporting of health care quality, prices 2Health News:Health care opinion leaders support public reporting of health care quality, prices 3Health News:New HPV vaccine under study 2Health News:Eating disorders in adolescents 2Health News:Eating disorders in adolescents 3Health News:Stress hormone may hasten the progression of certain blood cancers 2Health News:Stress hormone may hasten the progression of certain blood cancers 3Health News:ARJO / Getinge / Maquet Announces New West Coast Showroom Opening 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: